Clinical safety of biosimilar recombinant human erythropoietins

Ivo L Abraham, Karen MacDonald

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

A "biosimilar" or "similar biological medicinal product" is a biological agent that is similar in terms of quality, safety, and efficacy to an authorized reference biological medicine. Since the expiration of the epoetin alfa patent in Europe, three agents have received marketing authorization from the European Medicines Agency: Binocrit (epoetin alfa; aka Abseamed and Epoetin Alfa Hexal), Retacrit (epoetin zeta; aka Silapo), and Eporatio (epoetin theta; aka Biopoin and Ratioepo). Areas covered: Using the EMA dossiers and journal publications, this article reviews clinical safety data for these products, with emphasis on serious/severe adverse events and a special consideration of immunogenicity, venous thromboembolism, and mortality. Expert opinion: A review of the available safety evidence shows that all three agents discussed have similar safety profiles. None were statistically higher on safety parameters to what is known about ESA as a class, when stratified by population. As with ESAs in general, immunogenicity, venous thromboembolism, and mortality are all concerns. What is known about ESAs regarding safety can be extended to biosimilar erythropoietins. Since biosimilars are unique, complex biological molecules, safety profiles may evolve from common to differentiated, once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific effectiveness and safety profiles. Statistically, out of the commercially available formulations of the three products reviewed, no single product is less or more safe.

Original languageEnglish (US)
Pages (from-to)819-840
Number of pages22
JournalExpert Opinion on Drug Safety
Volume11
Issue number5
DOIs
StatePublished - Sep 2012

Fingerprint

Biosimilar Pharmaceuticals
Erythropoietin
Epoetin Alfa
Safety
Venous Thromboembolism
Mortality
Expert Testimony
Biological Factors
Anniversaries and Special Events
Marketing

Keywords

  • biosimilar pharmaceuticals
  • biosimilars
  • drug safety
  • erythropoietin
  • recombinant proteins
  • safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical safety of biosimilar recombinant human erythropoietins. / Abraham, Ivo L; MacDonald, Karen.

In: Expert Opinion on Drug Safety, Vol. 11, No. 5, 09.2012, p. 819-840.

Research output: Contribution to journalArticle

@article{e54b28e21e404997bd4cdfe0d78d0d02,
title = "Clinical safety of biosimilar recombinant human erythropoietins",
abstract = "A {"}biosimilar{"} or {"}similar biological medicinal product{"} is a biological agent that is similar in terms of quality, safety, and efficacy to an authorized reference biological medicine. Since the expiration of the epoetin alfa patent in Europe, three agents have received marketing authorization from the European Medicines Agency: Binocrit (epoetin alfa; aka Abseamed and Epoetin Alfa Hexal), Retacrit (epoetin zeta; aka Silapo), and Eporatio (epoetin theta; aka Biopoin and Ratioepo). Areas covered: Using the EMA dossiers and journal publications, this article reviews clinical safety data for these products, with emphasis on serious/severe adverse events and a special consideration of immunogenicity, venous thromboembolism, and mortality. Expert opinion: A review of the available safety evidence shows that all three agents discussed have similar safety profiles. None were statistically higher on safety parameters to what is known about ESA as a class, when stratified by population. As with ESAs in general, immunogenicity, venous thromboembolism, and mortality are all concerns. What is known about ESAs regarding safety can be extended to biosimilar erythropoietins. Since biosimilars are unique, complex biological molecules, safety profiles may evolve from common to differentiated, once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific effectiveness and safety profiles. Statistically, out of the commercially available formulations of the three products reviewed, no single product is less or more safe.",
keywords = "biosimilar pharmaceuticals, biosimilars, drug safety, erythropoietin, recombinant proteins, safety",
author = "Abraham, {Ivo L} and Karen MacDonald",
year = "2012",
month = "9",
doi = "10.1517/14740338.2012.712681",
language = "English (US)",
volume = "11",
pages = "819--840",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Clinical safety of biosimilar recombinant human erythropoietins

AU - Abraham, Ivo L

AU - MacDonald, Karen

PY - 2012/9

Y1 - 2012/9

N2 - A "biosimilar" or "similar biological medicinal product" is a biological agent that is similar in terms of quality, safety, and efficacy to an authorized reference biological medicine. Since the expiration of the epoetin alfa patent in Europe, three agents have received marketing authorization from the European Medicines Agency: Binocrit (epoetin alfa; aka Abseamed and Epoetin Alfa Hexal), Retacrit (epoetin zeta; aka Silapo), and Eporatio (epoetin theta; aka Biopoin and Ratioepo). Areas covered: Using the EMA dossiers and journal publications, this article reviews clinical safety data for these products, with emphasis on serious/severe adverse events and a special consideration of immunogenicity, venous thromboembolism, and mortality. Expert opinion: A review of the available safety evidence shows that all three agents discussed have similar safety profiles. None were statistically higher on safety parameters to what is known about ESA as a class, when stratified by population. As with ESAs in general, immunogenicity, venous thromboembolism, and mortality are all concerns. What is known about ESAs regarding safety can be extended to biosimilar erythropoietins. Since biosimilars are unique, complex biological molecules, safety profiles may evolve from common to differentiated, once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific effectiveness and safety profiles. Statistically, out of the commercially available formulations of the three products reviewed, no single product is less or more safe.

AB - A "biosimilar" or "similar biological medicinal product" is a biological agent that is similar in terms of quality, safety, and efficacy to an authorized reference biological medicine. Since the expiration of the epoetin alfa patent in Europe, three agents have received marketing authorization from the European Medicines Agency: Binocrit (epoetin alfa; aka Abseamed and Epoetin Alfa Hexal), Retacrit (epoetin zeta; aka Silapo), and Eporatio (epoetin theta; aka Biopoin and Ratioepo). Areas covered: Using the EMA dossiers and journal publications, this article reviews clinical safety data for these products, with emphasis on serious/severe adverse events and a special consideration of immunogenicity, venous thromboembolism, and mortality. Expert opinion: A review of the available safety evidence shows that all three agents discussed have similar safety profiles. None were statistically higher on safety parameters to what is known about ESA as a class, when stratified by population. As with ESAs in general, immunogenicity, venous thromboembolism, and mortality are all concerns. What is known about ESAs regarding safety can be extended to biosimilar erythropoietins. Since biosimilars are unique, complex biological molecules, safety profiles may evolve from common to differentiated, once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific effectiveness and safety profiles. Statistically, out of the commercially available formulations of the three products reviewed, no single product is less or more safe.

KW - biosimilar pharmaceuticals

KW - biosimilars

KW - drug safety

KW - erythropoietin

KW - recombinant proteins

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84865461168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865461168&partnerID=8YFLogxK

U2 - 10.1517/14740338.2012.712681

DO - 10.1517/14740338.2012.712681

M3 - Article

C2 - 22880621

AN - SCOPUS:84865461168

VL - 11

SP - 819

EP - 840

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 5

ER -